We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease.
- Authors
Portlock, Carol S; Donnelly, Gerard B; Qin, Jing; Straus, David; Yahalom, Joachim; Zelenetz, Andrew; Noy, Ariela; O'Connor, Owen; Horwitz, Steven; Moskowitz, Craig; Filippa, Daniel A
- Abstract
The prognostic significance of CD20 positive classical Hodgkin's disease (cHD) is uncertain. All cHD cases referred to the Memorial Sloan-Kettering Cancer Center (MSKCC) were retrospectively identified (5/92-11/00); the samples were immunostained, and clinical data ascertained. Cases were re-reviewed without knowledge of clinical outcome. Univariate and multivariate analyses were performed 248 patients had cHD: 28 CD20(+) (11%); 220 CD20(-). All clinical characteristics were comparable except haemoglobin level at presentation. With a median follow-up of 29.2 months, significant prognostic factors in multivariate analysis were: CD20 positivity, elevated white blood cell count (WBC) and low absolute lymphocyte count for time-to treatment failure (TTF); and for overall survival (OS), CD20 positivity, elevated WBC count, bone marrow involvement and age >/=45 years. TTF was significantly poorer for ABVD-treated patients with CD20(+) cHD as compared with CD20(-) cHD. Among 167 patients treated at MSKCC, both TTF (P < 0.0001) and OS (P = 0.017) were significantly decreased in CD20(+) patients as compared with CD20(-) cHD. CD20(+) cHD is a poor prognostic factor for TTF and OS. All cHD cases should be immunophenotyped for CD20. A large prospective trial is needed to confirm these findings.
- Publication
British journal of haematology, 2004, Vol 125, Issue 6, p701
- ISSN
0007-1048
- Publication type
Journal Article
- DOI
10.1111/j.1365-2141.2004.04964.x